Sandostatin Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Alerts
• Clinical Trials

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Condition:   Neuroendocrine CarcinomaInterventions:   Biological: Recombinant Interferon Alfa-2b;   Drug: Octreotide Acetate;   Biological: BevacizumabSponsor:   National Cancer Institute (NCI)Active, not recruiting - verified September 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 5, 2007 Category: Research Source Type: clinical trials